MB-107(March Biosciences)

N/A

Report date: 2023/11/23 17:36:12

Base Information

Drug NameMB-107(March Biosciences)
Drug Alias NameAutologus CD7 CAR T therapy(March Biosciences)MB-107(March Biosciences)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsT-cell antigen CD7 modulators
TargetsT-cell antigen CD7
Therapy Area/IndicationsLymphoma, T-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMarch Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesMarch Biosciences Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, T-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A